Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AeroVanc

Small molecule · Inhibitor of bacterial cell wall · developed by Savara

Phase 1 Most advanced trial (none active)

SVRA Developer

1 Registered trials

What is AeroVanc?

AeroVanc is vancomycin hydrochloride formulated as a dry powder for inhalation. It is studied in cystic fibrosis patients for pulmonary delivery of the antibiotic.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: bacterial cell wall
Mechanism: Inhibitor of bacterial cell wall
Therapy area: Respiratory
Developer: Savara Inc. (SVRA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01537666	Phase 1	Healthy	Completed	SVRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic FibrosisHealthy

Sources

ClinicalTrials.gov NCT01537666

Updated Oct 3, 2026. Something wrong or missing? Report it on the SVRA page.

Follow SVRA, the company behind AeroVanc

See SVRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SVRA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z